Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
62.22
-0.41 (-0.65%)
At close: Feb 27, 2026, 4:00 PM EST
62.00
-0.22 (-0.35%)
After-hours: Feb 27, 2026, 7:28 PM EST
Cytokinetics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Operating Revenue | 88.04 | 18.47 | 7.53 | 7.59 | 70.43 | |
| Other Revenue | - | - | - | 87 | - | |
| Revenue | 88.04 | 18.47 | 7.53 | 94.59 | 70.43 | |
| Revenue Growth (YoY) | 376.56% | 145.34% | -92.04% | 34.30% | 26.15% | |
| Cost of Revenue | 416.03 | 339.41 | 330.12 | 240.81 | 159.94 | |
| Gross Profit | -327.99 | -320.93 | -322.59 | -146.23 | -89.51 | |
| Selling, General & Admin | 284.27 | 215.31 | 173.61 | 177.98 | 96.8 | |
| Operating Expenses | 284.27 | 215.31 | 173.61 | 177.98 | 96.8 | |
| Operating Income | -612.26 | -536.25 | -496.21 | -324.2 | -186.31 | |
| Interest Expense | -103.87 | -86.51 | -57.67 | -51.16 | -29.33 | |
| Interest & Investment Income | 48.42 | 51.53 | 27.63 | 11.34 | 0.33 | |
| Other Non Operating Income (Expenses) | 4 | -18.3 | - | - | - | |
| EBT Excluding Unusual Items | -663.71 | -589.53 | -526.24 | -364.02 | -215.31 | |
| Other Unusual Items | -121.25 | - | - | -24.94 | - | |
| Pretax Income | -784.96 | -589.53 | -526.24 | -388.96 | -215.31 | |
| Net Income | -784.96 | -589.53 | -526.24 | -388.96 | -215.31 | |
| Net Income to Common | -784.96 | -589.53 | -526.24 | -388.96 | -215.31 | |
| Shares Outstanding (Basic) | 120 | 112 | 97 | 90 | 77 | |
| Shares Outstanding (Diluted) | 120 | 112 | 97 | 90 | 77 | |
| Shares Change (YoY) | 7.26% | 16.01% | 7.46% | 16.83% | 19.16% | |
| EPS (Basic) | -6.54 | -5.26 | -5.45 | -4.33 | -2.80 | |
| EPS (Diluted) | -6.54 | -5.26 | -5.45 | -4.33 | -2.80 | |
| Free Cash Flow | - | -399.8 | -415.75 | -310.85 | -191.39 | |
| Free Cash Flow Per Share | - | -3.57 | -4.31 | -3.46 | -2.49 | |
| Gross Margin | - | - | - | -154.59% | -127.09% | |
| Operating Margin | -695.44% | -2902.72% | -6589.71% | -342.75% | -264.54% | |
| Profit Margin | -891.60% | -3191.11% | -6988.63% | -411.21% | -305.72% | |
| Free Cash Flow Margin | - | -2164.10% | -5521.23% | -328.64% | -271.76% | |
| EBITDA | -602.57 | -526.72 | -484.31 | -318.39 | -184.04 | |
| EBITDA Margin | - | - | - | - | -261.31% | |
| D&A For EBITDA | 9.69 | 9.53 | 11.89 | 5.81 | 2.28 | |
| EBIT | -612.26 | -536.25 | -496.21 | -324.2 | -186.31 | |
| EBIT Margin | - | - | - | - | -264.54% | |
| Revenue as Reported | 88.04 | 18.47 | 7.53 | 94.59 | 70.43 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.